428 related articles for article (PubMed ID: 34475188)
1. Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators.
Spayne J; Hesketh T
BMJ Open; 2021 Sep; 11(9):e052016. PubMed ID: 34475188
[TBL] [Abstract][Full Text] [Related]
2. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
3. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.
Bruni L; Diaz M; Barrionuevo-Rosas L; Herrero R; Bray F; Bosch FX; de Sanjosé S; Castellsagué X
Lancet Glob Health; 2016 Jul; 4(7):e453-63. PubMed ID: 27340003
[TBL] [Abstract][Full Text] [Related]
4. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
5. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
[TBL] [Abstract][Full Text] [Related]
6. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit M; Brisson M; Portnoy A; Hutubessy R
Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
9. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
[TBL] [Abstract][Full Text] [Related]
10. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis.
Prem K; Choi YH; Bénard É; Burger EA; Hadley L; Laprise JF; Regan MC; Drolet M; Sy S; Abbas K; Portnoy A; Kim JJ; Brisson M; Jit M
BMC Med; 2023 Aug; 21(1):313. PubMed ID: 37635227
[TBL] [Abstract][Full Text] [Related]
11. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
[TBL] [Abstract][Full Text] [Related]
12. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
[TBL] [Abstract][Full Text] [Related]
13. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
14. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
[TBL] [Abstract][Full Text] [Related]
15. Covid-19 pandemic and equity of global human papillomavirus vaccination: descriptive study of World Health Organization-Unicef vaccination coverage estimates.
Casey RM; Akaba H; Hyde TB; Bloem P
BMJ Med; 2024; 3(1):e000726. PubMed ID: 38293682
[TBL] [Abstract][Full Text] [Related]
16. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019.
Bruni L; Saura-Lázaro A; Montoliu A; Brotons M; Alemany L; Diallo MS; Afsar OZ; LaMontagne DS; Mosina L; Contreras M; Velandia-González M; Pastore R; Gacic-Dobo M; Bloem P
Prev Med; 2021 Mar; 144():106399. PubMed ID: 33388322
[TBL] [Abstract][Full Text] [Related]
17. Correlates of human papillomavirus vaccine coverage: a state-level analysis.
Moss JL; Reiter PL; Brewer NT
Sex Transm Dis; 2015 Feb; 42(2):71-5. PubMed ID: 25585064
[TBL] [Abstract][Full Text] [Related]
18. Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact.
Rodin D; Burger EA; Atun R; Barton M; Gospodarowicz M; Grover S; Hanna TP; Jaffray DA; Knaul FM; Lievens Y; Zubizarreta E; Milosevic M
Lancet Oncol; 2019 Jul; 20(7):915-923. PubMed ID: 31151906
[TBL] [Abstract][Full Text] [Related]
19. National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.
Mphuru A; Li AJ; Kyesi F; Mwengee W; Mazige F; Nshunju R; Shayo B; Giattas MR; Loharikar A; Lyimo D
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A2-A9. PubMed ID: 33962839
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide.
Owsianka B; Gańczak M
Przegl Epidemiol; 2015; 69(1):53-8, 151-5. PubMed ID: 25862448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]